Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)

Dr. John Swisher

Intensive Care Medicine
Cherokee Health Systems
2240 Sutherland Ave Ste 103, 
Knoxville, TN 
Offers Telehealth
Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Cherokee Health Systems
2240 Sutherland Ave Ste 103, 
Knoxville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Swisher is an Intensive Care Medicine provider in Knoxville, Tennessee. Dr. Swisher is rated as an Experienced provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Lung Metastases, Gastrostomy, and Carotid Artery Surgery.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 3 clinical trials in the study of Heart Failure with Preserved Ejection Fraction (HFpEF).

Specialties
Intensive Care Medicine
Licenses
Critical Care Medicine in TN
Hospital Affiliations
Fort Loudoun Medical Center
Fort Sanders Regional Medical Center
Wellmont Bristol Regional Medical Center
Physicians Regional Medical Center
Parkwest Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Cherokee Health Systems
2240 Sutherland Ave Ste 103, Knoxville, TN 37919
Other Locations
Office
6473 Kingston Pike, Knoxville, TN 37919

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF)
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drug: Sotatercept
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

4 Total Publications

Therapeutic options for patients with pulmonary hypertension and interstitial lung disease.
Therapeutic options for patients with pulmonary hypertension and interstitial lung disease.
Journal: Therapeutic advances in respiratory disease
Published: June 21, 2025
Similar Doctors
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Eric Weaver
Intensive Care Medicine
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Eric Weaver
Intensive Care Medicine

Cherokee Health Systems

2240 Sutherland Ave Ste 103, 
Knoxville, TN 
 (8.3 miles away)
865-588-8831
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Weaver is an Intensive Care Medicine provider in Knoxville, Tennessee. Dr. Weaver is rated as a Distinguished provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Pulmonary Hypertension, Pulmonary Fibrosis, Pulmonary Veno-Occlusive Disease, Gastrostomy, and Carotid Artery Surgery.

Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Andrews Paul
Intensive Care Medicine
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Andrews Paul
Intensive Care Medicine

Parkwest Medical Center

9352 Park West Blvd, 
Knoxville, TN 
 (2.9 miles away)
865-373-1974
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrews Paul is an Intensive Care Medicine provider in Knoxville, Tennessee. Dr. Paul is rated as a Distinguished provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Hypovolemic Shock, Periodic Limb Movement Disorder, Obstructive Sleep Apnea, Atypical Pneumonia, and Gastrostomy.

Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Ralph Maroun
Intensive Care Medicine
Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Ralph Maroun
Intensive Care Medicine

Office

6473 Kingston Pike, 
Knoxville, TN 
 (8.3 miles away)
865-588-8831
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ralph Maroun is an Intensive Care Medicine provider in Knoxville, Tennessee. Dr. Maroun is rated as an Advanced provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Pneumonia, Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, and Hospital-Acquired Pneumonia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Swisher's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 33 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile